GAIL's EBITDA came in 10% below JEFe on a large miss in the trading segment even as the petrochemical segment came in ahead of JEFe. Lower than expected depreciation and higher other income helped PAT beat JEFe by 4%.
US on a steady growth path; sizeable launches lined up in FY23: Cipla continues to see strong traction for its gProventil (albuterol inhaler) launch in the US where it has garnered 13.2% volume share. 4Q US sales at $138 m de
We continue to see Dabur as the key beneficiary of the wave of naturals and Ayurveda and Dabur is also driving growth by improving its distribution, direct reach and strengthening its business in regions where its presence is
EOP has simplified the holding structure of Manyata (MPPL) SPV, which has resulted in an improved share of distribution in the form of dividends, resulting in 78% of the distribution now being tax-free for unitholders vs 55%
Scaling new heights. TVS's margin performance has surprised the Street positively for the fourth consecutive quarter, with EBITDA margins of 10.1% in 4Q FY21 (vs Street expectation of 8.5%). The double-digit milestone was ach